Primerica (PRI)
NYSEFinancialsInsurance - LifeSnapshot 2026-10-30
$281.09-0.87%
Close 2026-10-30 · 1-day change
NYSEFinancialsInsurance - LifeSnapshot 2026-10-30
Research Workspace
Put PRI beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Financials is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Increase earnings per share to at least $6.33 in FY 2025: Comparison needs review.
View ThesisRevenue is growing steadily — about 9% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityManagement screens strong on capital allocation, earnings delivery, the balance sheet.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskPRI’s thesis rests on steady earnings and modestly rising revenue, despite mixed earnings quality. Revenue growth increased from 8% in Q1 FY2026 to 9% in Q2. Q2 FY2026 non-GAAP earnings beat consensus by 7.6%. PRI trades at 3.5× P/B versus a 1.3× peer median, reflecting expectations below our forecast. That premium is close to its own 3.7× history. The specific pillar risk is the FY 2025 EPS target comparison, which the desk says needs review. Our model puts the next-quarter miss probability at 25%. Peer multiples imply a price roughly in line with where it trades (about fair); the thesis is on watch; this read is provisional.
Trailing returns as of 2026-10-30. PRI is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 8 analysts currently covering PRI (as of Oct 2026).
Based on 3 Wall Street analysts offering 12-month price targets for PRI in the last 4 months.
Continue this research
Compare PRI with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| PRI Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 13 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Life & Health Insurance — fair value, gap to price, and forward P/E.
Compare the value case
Put PRI next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Grow Investment and Savings Products sales and client assets
Investment product growth aligns with management's growth objectives.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $281.09
The last 12 months of price, then the range of analyst 12-month targets from today’s $281.09.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Grow Investment and Savings Products sales and client assets
Rising markets positively impact investment sales outlook.
Advances: Grow Investment and Savings Products sales and client assets
Rising markets positively impact investment sales outlook.
Threatens: Grow Investment and Savings Products sales and client assets
Shrinking sales force may hinder growth in investment products.
Advances: Increase EPS
Earnings beat indicates strong performance and growth potential.
Advances: Increase revenue
Positive earnings review supports revenue growth.
Weakening market poses risks to revenue growth.
Hedge fund selling indicates potential loss of confidence.